Loading clinical trials...

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

The Timing for Liraglutide in Patients Remaining Obese at 6 Months After Metabolic Surgery: an Observational Study

NCT07374445•The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are: \[primary hypothesis 1\] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery. \[primary hypothesis 2\] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients 6 months after metabolic surgery;
•18 years ≤ age ≤ 65 years;
•Body Mass Index (BMI) ≥ 28 kg/m\^2

Exclusion Criteria

•allergy to liraglutide, severe hepatic or renal impairment (eGFR \<60 mL/min/1.73 m² or ALT/AST ≥3× ULN)
•history of medullary thyroid carcinoma, MEN-2 or other malignancies
•pancreatitis or severe gastrointestinal disease, pregnancy or lactation
•use of anti-obesity drugs or other interventional trials within 3 months or major uncontrolled illness
•Patients were discontinued if withdrawn, intolerant, lost to follow-up, or developed severe adverse events.

Locations (1)

Nanjing Drum Tower Hospital

Nanjing, China

Key Dates

Start Date

September 1, 2023

Primary Completion Date

June 1, 2025

Completion Date

June 1, 2025

Last Updated

January 28, 2026

Enrollment

100

ACTUAL participants

Conditions

ObesityWeight LossBariatric Surgery

Interventions

Liraglutide injection

DRUG

Diet and exercise guidelines

BEHAVIORAL

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss